Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Academisch Ziekenhuis Leiden (H O D N Lumc) is currently processing 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 5 actions are spread across 5 distinct examiners and 5 distinct art units. This total lack of overlap indicates that every pending matter is being examined independently by different personnel in different administrative groups. Such a distribution suggests that the company's intellectual property in this space is being evaluated from various technical perspectives within the 5 distinct art units.
REILLY, SOPHIA JANE is the busiest examiner, managing 1 of the 5 pending office actions. Since there are 5 distinct art units involved, the company must adapt to five different examination environments. The distribution across 5 distinct examiners ensures that the prosecution of the 5 pending office actions is not centralized under any single individual's discretion. Practitioners should prepare for varied examiner perspectives, as the 5 distinct art units may have different internal guidelines or prior art focuses within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §103 only | 1 (25%) |
| §102 only | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LABRANCHE, BROOKE N | 1 | 72.1% | +17.0% |
| DELEO, VICTORIA LYNN | 1 | 41.4% | -44.4% |
| RAUBENSTRAW, TYLER ALLEN | 1 | 71.2% | +30.6% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17919138 | METHODS FOR INDUCTION OF ENDOGENOUS TANDEM DUPLICATION EVENTS | DELEO, VICTORIA LYNN | — |
| 16521430 | T CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | GUSTILO, ESTELLA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030356 | SURGICAL TOOL, SYSTEM AND METHOD | LABRANCHE, BROOKE N | 28d |
| 17760105 | Apparatus for Prevention of Apnea | RAUBENSTRAW, TYLER ALLEN | — |
| 16521430 | T CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 3771 | 1 |
| 1662 | 1 |
| 3785 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030356 | SURGICAL TOOL, SYSTEM AND METHOD | LABRANCHE, BROOKE N | 3771 | §102 | Non-Final OA | 28d | Pending | Apr 05, 2023 |
| 17919138 | METHODS FOR INDUCTION OF ENDOGENOUS TANDEM DUPLICATION EVENTS | DELEO, VICTORIA LYNN | 1662 | §101§102§103§112 | Final Rejection | — | Pending | Oct 14, 2022 |
| 17760105 | Apparatus for Prevention of Apnea | RAUBENSTRAW, TYLER ALLEN | 3785 | §103 | Non-Final OA | — | Pending | Aug 04, 2022 |
| 16521430 | T CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | GUSTILO, ESTELLA M | 1646 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 24, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAcademisch Ziekenhuis Leiden (H O D N Lumc) has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Brooke N Labranche has the most, with 1 of Academisch Ziekenhuis Leiden (H O D N Lumc)'s pending office actions.
Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.
